netilmicin

netilmicin
IUPAC name	(2S)-4-O-[3-O-(2,6-diamino-2,3,4,6-tetradeoxy-α-D-erythro-hexopyranosyl)-6-O-methyl-β-D-ribo-hexopyranosyl]-2-deoxy-N1-ethyl-D-streptamine
CAS number	56391-57-2
PubChem	441341
DrugBank	DB00975
ChemSpiderID	390152
Molecular weight	475.58 g/mol
Chemical formula	C21H41N5O7

netilmicin. Netilmicin is a semisynthetic aminoglycoside antibiotic derived from sisomicin, developed to combat infections caused by Gram-negative bacteria while exhibiting reduced toxicity compared to earlier agents in its class. It is primarily used in clinical settings for serious infections such as sepsis, complicated urinary tract infections, and hospital-acquired pneumonia, particularly when caused by organisms like Pseudomonas aeruginosa. The drug's development by the Schering Corporation in the 1970s represented a targeted effort within the broader antibiotic resistance crisis to create safer therapeutic options.

Chemical properties

Netilmicin sulfate is a white, crystalline powder that is highly soluble in water and practically insoluble in common organic solvents like chloroform or ethyl acetate. Its chemical structure features a central 2-deoxystreptamine ring linked to two amino sugar moieties, a modification from its parent compound that contributes to its stability. The molecule's polarity and cationic nature at physiological pH influence its pharmacokinetic behavior and interaction with bacterial ribosomes. Analytical characterization typically employs techniques such as high-performance liquid chromatography and mass spectrometry.

Medical uses

Clinically, netilmicin is indicated for the treatment of serious infections documented or suspected to be caused by susceptible strains of aerobic Gram-negative bacteria. This includes life-threatening conditions like bacteremia and peritonitis often encountered in hospital settings such as the intensive care unit. Its use is generally reserved for cases where less toxic antibiotics are ineffective, following guidelines from institutions like the World Health Organization and the Infectious Diseases Society of America. It is sometimes employed in synergistic combination with beta-lactam antibiotics like penicillin for infections involving Enterococcus faecalis.

Mechanism of action

Netilmicin exerts its bactericidal effect by binding irreversibly to the 30S subunit of the bacterial ribosome, a process facilitated by its interaction with specific regions of ribosomal RNA. This binding interferes with the initiation complex of protein synthesis and causes misreading of the genetic code carried by messenger RNA, leading to the production of nonfunctional or toxic peptides. The drug's uptake into bacterial cells is an energy-dependent process that is enhanced by the co-administration of cell wall-active agents like vancomycin.

Adverse effects

The most significant adverse effects associated with netilmicin are nephrotoxicity and ototoxicity, which are class effects of aminoglycosides but occur at a potentially lower incidence compared to drugs like gentamicin. Ototoxicity can manifest as irreversible damage to the cochlea or vestibular system, leading to hearing loss or balance disorders. Other potential reactions include neuromuscular blockade, which can exacerbate conditions like myasthenia gravis, and rare hypersensitivity reactions. Monitoring protocols, including assessments of renal function and auditory brainstem response, are critical during therapy.

Pharmacokinetics

Following intramuscular or intravenous administration, netilmicin is rapidly absorbed and distributes widely into extracellular fluid, though penetration into the cerebrospinal fluid and vitreous humour is poor. It is not metabolized and is excreted almost exclusively unchanged in the urine via glomerular filtration. Its elimination half-life is prolonged in patients with impaired renal function or in conditions like cystic fibrosis, necessitating dosage adjustments. Therapeutic drug monitoring, measuring peak and trough serum concentrations, is standard practice to optimize efficacy and minimize toxicity.

History and society

Netilmicin was synthesized in the laboratories of the Schering Corporation in the United States during the 1970s, a period marked by intense research into modifying existing aminoglycosides to overcome emerging bacterial resistance and toxicity. Its approval by the Food and Drug Administration added a valuable tool for treating infections in vulnerable populations. The drug's development and subsequent use reflect broader themes in 20th-century pharmacology, including the pharmaceutical industry's response to the challenges posed by organisms like Pseudomonas aeruginosa and the ongoing global struggle against antimicrobial resistance.

Category:Aminoglycoside antibiotics Category:World Health Organization essential medicines